This finding was confirmed with previous studies that chemotherapy could achieve similar clinical efficacy as EGFR-TKI therapy for non-small cell lung cancer (NSCLC) patients [35–37]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.